The weekly litigation news digest is live. Subscribe now

IP Verse

Pharmaceutical Composition Comprising Lenvatinib Mesylate - EP3606511

The patent EP3606511 was granted to Synthon on Apr 20, 2022. The application was filed on Apr 4, 2018 under application number EP18713995A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3606511

SYNTHON
Application Number
EP18713995A
Filing Date
Apr 4, 2018
Status
Granted And Under Opposition
Mar 18, 2022
Publication Date
Apr 20, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
TEVA PHARMACEUTICALSJan 18, 2023KRAUS & LEDERER PARTGMBBWITHDRAWN

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP1415987
DESCRIPTIONEP1797881
DESCRIPTIONEP2468281
INTERNATIONAL-SEARCH-REPORTEP1797881
INTERNATIONAL-SEARCH-REPORTUS2012077842
INTERNATIONAL-SEARCH-REPORTWO2017028660
OPPOSITIONEP1415987
OPPOSITIONEP1698623
OPPOSITIONEP1797881
OPPOSITIONEP1938842
OPPOSITIONUS2008131503
OPPOSITIONUS2012077842
OPPOSITIONWO2017028660

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents